本則回應

• Asdfgh標記此篇為：⭕ 含有正確訊息

  理由

  博瑞生物医药（苏州）股份有限公司確實於2020/2/12於上海證交所公告仿製訊息，但因面對美國吉利德公司擁有藥物應用的專利，博瑞生物醫藥回應，將藥物投入市場需要吉利德的授權，這一過程將會「存在重大不確定性」。

  出處

  http://static.sse.com.cn//disclosure/lis⋯fo/bulletin/star/c/688166_20200212_1.pdf
  http://www.sse.com.cn/assortment/stock/l⋯nnouncement/index.shtml?productId=688166
  https://www.nownews.com/news/20200212/3931303/

  http://static.sse.com.cn//disclosure/listedinfo/bulletin/star/c/688166_20200212_1.pdf

  Cannot get data from URL

  http://www.sse.com.cn/assortment/stock/list/info/announcement/index.shtml?productId=688166

  Cannot get data from URL

  https://www.nownews.com/news/20200212/3931303/

  Cannot get data from URL